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ABSTRACT

The aim of the present investigation is to purify, characterize, and determine the
chemical and biological properties of Porphyromonas gingivalis free
dihydroceramides (fDHC). Effects were tested by examination of human gingival
fibroblast morphologic changes in addition to their synthesis of prostaglandin E 2
(PGE 2 ) and prostaglandin F 2α (PGF 2α ) produced in vitro. Free dihydroceramides as
well as phosphoglycerol dihydroceramide (PGDHC), and de-esterified
phosphoglycerol dihydroceramide (PGDHC-C 15:0 ) were obtained by total lipid
extraction of P. gingivalis followed by high performance liquid chromatography
(HPLC). Confirmation and structural analysis was obtained by electrospray mass
spectrometry (ES-/+MS) and nuclear magnetic resonance spectroscopy (NMR). A
synthetic free dihydroceramide (A) was obtained, and its purification and structural
analysis was similar. Ethanol solvent served as a negative control, and PGDHC
served as a positive control. HGF were obtained from tissue samples of two
periodontally healthy volunteers during clinical crown lengthening procedures, and
cell cultures were introduced to 35 mm wells previously coated with ethanol or 20µg
of each lipid/well. Additional experimentation was carried out to investigate
fibroblast response to different concentrations of P. gingivalis fDHC. These
experiments were carried out in a similar manner except P. gingivalis fDHC were
studied at 0.2, 2, and 20 µg/35 mm well. After one hour, 30 ng of interleukin-1β (IL1β) was added to each sample. After 24 hours, supernatants were harvested and 100
ng of both deuterated prostaglandin E 2 (DPGE 2 ) and prostaglandin F 2α (DPGF 2α )
vi

were added. Analyses were performed by derivatization of samples followed by gas
chromatograph mass spectrometry (GC-MS). HGF synthesis of PGF 2α was
unaffected for all lipids tested. IL-1β mediated HGF synthesis of PGE 2 was greater
for all treatment groups compared to control; however, statistical significance was
only achieved for PGDHC and P. gingivalis fDHC (p < .05). P. gingivalis PGDHC
and fDHC treated HGF resulted in similar PGE 2 synthesis approximately 1.8 fold
compared to ethanol vehicle. Morphologic changes suggestive of HGF atrophy and
apoptosis were evident only for PGDHC, and this was noted for the majority of
PGDHC experiments. These findings suggest that IL-1β mediated HGF secretion of
PGE 2 can occur even in the absence of a phosphate linkage and 15-carbon
isobranched methyl ester, but these structural elements seem to play an important role
in the induction of cellular morphological changes observed in phase contrast
microscopy.
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INTRODUCTION

Periodontal diseases include both gingivitis and periodontitis, which affect the
periodontal supporting tissues of teeth [1]. However, unlike gingivitis, periodontitis is
accompanied by apical migration of junctional epithelium, destruction of connective
tissue attachment, and alveolar bone loss [2, 3]. Approximately 30% of the adult U.S.
population has moderate periodontitis, with 5% of the adult population experiencing
severe periodontitis [4]. In addition, longer average lifespan has resulted in a 32-fold
increase in the number of older dentate individuals at risk of developing periodontitis.
More recently, epidemiological studies have shown that periodontal disease may be a
significant etiology of various systemic diseases including coronary heart disease,
diabetes, and COPD [5].
Periodontal diseases are typically infectious by nature and are a consequence of
biofilm formation[6-8]. Supragingival biofilm is predominantly composed of Grampositive aerobic microorganisms and creates and ecological niche enabling Gram
negative anaerobic flora to thrive [9]. Specific bacteria cultured from periodontal pockets
that have been described as more pathogenic than others include Aggregatibacter
actinomycetemcomitans, Prevotella intermedia, Tannerella forsythia, Porphyromonas
gingivalis, and Treponema denticola where the latter three have been categorized in the
red complex of bacteria by Socransky and coworkers [10, 11]. Persistence of these
microbes after periodontal therapy has been associated with negative outcomes [12].
Previous investigation has shown that P. gingivalis, a Gram-negative,
asaccharolytic, obligate anaerobic rod, is strongly associated with chronic periodontitis
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[13]. P. gingivalis produces a broad array of potential virulence factors involved in tissue
colonization and destruction as well as in host defense perturbation [14]. Among these
virulence factors, trypsin-like proteinases, called gingipains, have been purified and
characterized, and their functions and pathological roles in periodontitis have been
extensively investigated over the past decade [15]. Gingipains are responsible for most of
the extracellular and cell-bound proteolytic activities produced by P. gingivalis. P.
gingivalis is in close contact with the epithelium in periodontal pockets in vivo [16] and
can invade various cell lines, including epithelial cells [17], endothelial cells [18], and
fibroblasts in vitro [19].
The gingival epithelium is a stratified squamous epithelium that is an interface
between the external environment, which is exposed to bacterial challenges, and the
underlying periodontal tissue. The basal layer of the gingival epithelium is separated
from and attached to the connective tissue by the basal lamina. The gingival epithelium
can be divided into oral, sulcular, and junctional epithelia, based on their architecture.
The sulcular epithelium, which extends from the oral epithelium to the gingival sulcus
facing the teeth, and the junctional epithelium, which mediates the attachment of teeth to
gingiva, are not keratinized, in contrast to the oral gingival epithelium [20]. The sulcular
and the coronal margins of the junctional epithelium are in close contact with bacteria in
the gingival sulcus and appear to be crucial sites with regard to the development of
periodontal diseases. During periodontitis, loss of connective tissue attachment and bone
resorption associated with the formation of periodontal pockets is related to the
pathologic conversion of the junctional and the sulcular epithelium to a pocket
epithelium. Invasion of mammalian epithelial cells is an important strategy developed by
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pathogenic bacteria to evade the host immune system and cause tissue damage. Gingival
epithelial cells are the primary physical barrier to infections by periodontal pathogens in
vivo. While the epithelium was previously thought to be passive, Dale (2002) [21]
proposed a new perspective, assigning an active role to the epithelium in the host
response to bacterial infections. The epithelium reacts to bacterial challenges by signaling
host responses and integrating innate and acquired immune responses. This review
focuses on the current understanding of host epithelial cells and P. gingivalis interactions
in the pathogenesis of periodontitis. By contrast, periodontally healthy patients will
have either no detectable levels of P. gingivalis or only small quantities in subgingival
plaque samples [20]. High levels of P. gingivalis have been well correlated with severe
loss of connective tissue attachment, deep periodontal pockets, loss of alveolar bone, and
rapidly progressing periodontal disease [13, 22, 23]. The presence of
periodontopathogenic microorganisms is associated with an increase in inflammatory cell
infiltrate and cytokine production including interleukin-1β (IL-1β), interleukin-6 (IL-6),
interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), prostaglandin E 2 (PGE 2 ), as well
matrix metalloproteinases (MMPs), which recruit lymphocytes, fibroblasts, and
osteoclasts that damage the surrounding periodontal tissues [24].
Subgingival microflora, in general, elicit a complex host immune response
through virulence factors such as endotoxin, proteases, and lipopolysaccharide (LPS).
LPS is a cell wall constituent of Gram-negative microorganisms. The LPS molecule
contains three structural components: O-specific polysaccharide, core polysaccharide,
and lipid A. The lipid A portion of the molecule has been shown to be responsible for the
associated biological activity including inflammatory cell activation and inflammatory
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cytokine production, and its potency differs among different bacterial species [25].
Covalently linked to lipid A by either amide or ester linkages are even carbon-chain 2hydroxy and odd-chain isobranched 3-hydroxy fatty acids. Bacterial LPS acts by
associating with LPS-binding protein (LBP), and the LPS-LBP complex then binds to
Toll-like receptor-4 (TLR-4) resulting in downstream intracellular signal transduction
with activation of nuclear factor-kappa B (NF-κB) and eventual production of
proinflammatory cytokines[26, 27]. Toll-like receptors are among a number of pattern
recognition surface receptors that appear to play a role in pathogen recognition and
initiation of inflammatory and immune responses. Several TLR isoforms exists, and each
one has high specificity for binding a certain pathogen-associated molecular pattern
(PAMP) [28]. Evidence has demonstrated that “atypical” P. gingivalis LPS,
peptidoglycan, and lipoprotein binds TLR-2 receptors [29, 30], and TLR4 appears to be
specific for LPS [30].
Bacterial complex lipids recovered in diseased gingival tissues include a class of
sphingolipids, called dihydroceramides, and are produced by P. gingivalis [31]. A
ceramide is a lipid molecule composed of a sphingosine and a fatty acid. Ceramides are
found in high concentrations within the mammalian cell membrane phospholipid bilayer.
Ceramides have also been key players in cellular response to stress and apoptosis [32].
Hydrolysis of sphingomyelin by acid sphingomyelinase results in the release of ceramide,
while synthesis of ceramide is catalyzed by the serine-palmitoyl-CoA transferase and
ceramide-synthase [33]. Sphingomyelin is a type of sphingolipid found in mammalian
cell membranes most significantly in the myelin sheath around certain nerve cell axons.
It usually consists of phosphorylcholine and ceramide. Sphingomyelin is an important
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facilitator of signal transduction. Sphingolipids are derived from the aliphatic amino
alcohol sphingosine and play an important role in both signal transmission and cell
recognition. Ceramide molecules reorganize the cell membrane leading to the formation
of large, distinct ceramide-enriched membrane domains, termed rafts, that serve to cluster
and aggregate activated receptor molecules [34]. Besides the important role of ceramide
in receptor-induced cell death, several studies demonstrate a central role of ceramide in
UV-light, irradiation and triggered cell death [35]. Several recent publications indicate
that ceramide is also present in mitochondria, and that mitochondrial ceramide may play
a role in apoptosis. Mitochondrial ceramide seems to be generated through the activity of
the acid sphingomyelinase, which has been shown to reside in the space between the
inner and outer mitochondrial membrane [36]. Although many studies indicate a central
role of ceramide for the induction of apoptosis after an acute stimulus, only a few data
exist that demonstrate a contribution of ceramide to a dysregulation of apoptosis in
human disorders. Diseases that have been shown to be caused by dysregulation of cellular
ceramide include neurological syndromes, including hereditary sensoric neuropathy Type
I and II. Hereditary sensoric neuropathy Type I is caused by a mutation of serine–
palmitoyltransferase 1 and an increased cellular ceramide concentration, which seems to
be causally linked to degeneration of peripheral sensory neurons [37, 38]. Cellular
ceramide levels are also increased in the Batten’s syndrome, which is caused by a
mutation of palmitoyl-thioesterase and of CLN3 resulting in neuronal cell death with
cognitive and motor decline, seizures and blindness [39]. Finally, experiments on
Drosophila also suggest an involvement of ceramide in retina degeneration, although it is
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not known whether similar mechanisms are effective in the corresponding human disease
[40, 41].
Ceramides have been linked to periodontal pathogenesis since they are readily
recovered from disease gingival tissues and root surfaces of hopeless teeth extracted due
to severe periodontitis [42]. More specifically, P. gingivalis, dihydroceramides have
been detected in lipid extracts of calculus-contaminated teeth, subgingival calculus,
subgingival plaque and in diseased gingival tissues. This evidence suggests that diseased
gingival tissues are not simply contaminated with subgingival plaque. Regardless of the
processes resulting in bacterial lipid accumulation in periodontitis tissue samples or
metabolic clearance of these bacterial lipids, the recovery of phosphorylated
dihydroceramides in diseased gingival tissues indicates that the biological properties of
the contaminating bacterial lipids must be understood within the context of disease
promotion [42].
Sharing structural similarity to lipid A, previous chemical analysis via gas
chromatography-mass spectrometry (GC-MS) has shown that these bacterial ceramide
lipids also contains 3-hydroxy fatty acids linked to a long chain base of either 2-amino,3octadecanediol or 2-amino1,3-nondecanediol amide linkage [31]. Bacterial ceramides
share basic structural characteristics with mammalian ceramides and are therefore
expected to promote cell activation in host cells normally susceptible to elevated levels of
mammalian ceramides [43, 44]. P. gingivalis synthesizes free, phosphoethanolamine,
and phosphoglycerol dihydroceramides that share a core lipid structure consisting of
three long chain bases (17, 18, and 19 carbon aliphatic chains) in amide linkage to 3-OH
isobranched C 17:O [45, 46]. The phosphoglycerol dihydroceramide class may be
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substituted with isobranched C 15:O linked to the beta hydroxyl of 3-OH isobranched C 17:O
[46]. These bacterial lipids are not components of lipopolysaccharide and their recovery
in gingival tissues is not attributable to coincident bacterial invasion [31, 45]. In
addition, mammalian cells have not been shown to produce 3-OH isobranched C 17:O , and
this fatty acid has been recovered in lipid extracts of periodontally diseased human
cementum and gingival tissues [45].
P. gingivalis dihydroceramides can be extracted with organic solvents directly
from the bacterial pellet obtained after growth of the organism, centrifugation, and
lyophillization following a protocol described by Bligh and Dyer, and Garbus et al [47,
48]. Following total lipid extraction, select dihydroceramides are separated by direct and
reverse phase high performance liquid chromatography (HPLC) [46]. Confirmation of
these fractions is possible with electrospray (ESI-MS) or gas chromatograph mass
spectrometry (GC-MS) prior to experimentation [46].
For many years, periodontal therapy only aimed to remove the etiologic factors
from the root surface and recontour hard tissue anatomical defects. This approach
minimizes periodontal inflammation and creates a clinical situation that is more easily
accessible for home and professional oral hygiene practices. With advances in tissue
engineering and the importance of esthetics, regeneration of the periodontal attachment
apparatus has been considered the ultimate goal of periodontal treatment. The
periodontium is a complex organ comprised of gingiva, periodontal ligament, alveolar
bone, and cementum. To achieve successful periodontal regeneration, formation of an
epithelial seal, insertion of new connective tissue fibers into the root, reformation of a
new acellular cementum reformed on the root surface, and restoration of alveolar bone

7

are required [49]. However, the inhibition of periodontal regeneration after conventional
treatment modalities is due to proliferation of epithelial tissues into the periodontal defect
at a faster rate than mesenchymal tissues [50]. This leads to the formation of a long
junctional epithelium and prevents the selective migration, proliferation, and
differentiation of cells derived from the periodontal ligament (PDL) [51]. The concept
that only PDL cells have the potential to create a new connective tissue attachment has
been confirmed through investigation giving the basis for the clinical application of
guided tissue regeneration (GTR) [52]. However, the results obtained using the GTR
technique are reported to be unpredictable and of small magnitude [53, 54] possibly
because of postoperative infections and the inability to completely seal the healing area
[55]. Three basic components must be considered in periodontal tissue engineering: 1)
appropriate signals, 2) scaffolds/barriers to enable coronal population of the appropriate
cells from the PDL, and 3) cells from the PDL with regenerative potential. It has been
shown that PDL cells may prevent ankylosis and root resorption in addition to
regeneration of a new periodontal ligament with insertion into both tooth and bone. Also,
roots covered with osteoprogenitor cells induce cementum-like tissue formation
suggesting that cementoblast and osteoblast precursors commonly originate from the
alveolar bone [56, 57]. The formation of new bone and cementum varies from complete
absence to a thin layer of newly formed cementum with complete new bone formation
covering the entire previously denuded root surface. Moreover, it may be speculated that
differentiation of PDL cells is highly sensitive to differences in their microenvironments,
resulting in different types of periodontal healing. It has been shown that, [58] after
transplantation, the number of cells increases over time and reflects sustained
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proliferation. These newly transplanted cells migrate to the bone surface and express
osteoblast markers, for example osteopontin and bone sialoprotein, to facilitate
osteogenesis; cells that migrate to PDL express the same phenotypic markers as other
PDL cells. This confirms the hypothesis that, under some circumstances, PDL cells can
promote periodontal regeneration.
Independent of the periodontal disease status, the predominant cell type recovered
in gingival connective tissue is the fibroblast [59]. Fibroblasts play an important role in
the remodeling of extracellular matrix (ECM) by synthesizing connective tissue
components predominantly constituted of fibrillar collagens [60]. Fibroblasts respond to
various inflammatory cytokines and growth factors [61], and control the balance between
ECM synthesis and degradation [62]. A shift in this normal homeostasis can lead to
direct destruction of the periodontal connective tissue attachment apparatus and indirect
destruction of alveolar bone through increased synthesis and secretion of
proinflammatory cytokines (PGE 2 , IL-1β, IL-6, IL-8, and TNF-α) [63]. Gingival
fibroblasts exposure to bacterial lipids is expected given the impressive recovery of
bacterial lipids in diseased periodontal tissues [45, 64]. Fibroblasts are capable of
secreting high levels of prostaglandin E 2 (PGE 2 ) [65], a proinflammatory host factor with
ability to have adverse effects on bone and connective tissue homeostasis.
Previous investigation has described methods regarding human gingival fibroblast
culture from gingival tissues harvested during periodontal surgery [65]. Once cultures
have been obtained, one can apply fibroblasts to wells contaminated with
dihydroceramides, introduce IL-1β, and measure response via prostanoid quantification
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[46]. Methods of separation, derivatization, and chemical analysis of prostanoids have
also been previously described [66-68].
Prostaglandins are a subclass of eicosanoids, derived from arachidonic acid, and
are important mediators of inflammation. Prostaglandin production, more specifically
PGE 2 , has been strongly associated with periodontal pathogenesis [69]. Most notably, of
their many functions, prostaglandins are potent vasodilators and inducers of cytokine
production by various cells. In conjunction with proinflammatory cytokines, PGE 2 acts
on fibroblasts and osteoclasts, to induce MMP production, which is also a major
component to the destructive process of periodontitis [69]. As demonstrated in a murine
model, PGE 2 also appears to significantly facilitate osteoclastogenesis by enhancing
RANKL (receptor activator of nuclear factor-kappa B ligand) and depression of
osteoprotegerin (RANKL inhibitor) [70]. Therefore, PGE 2 association with destruction
of connective tissue attachment and alveolar bone supports its central importance in the
periodontal disease process. Previous investigation has associated PGE 2 with
periodontitis and suggests that its concentration in gingival crevicular fluid increases in
gingivitis relative to health and is at very high concentration during periods of
periodontal disease progression [71].
Previous investigation has shown prostaglandin hypersecretory response of
gingival fibroblasts to both phosphorylated dihydroceramide classes in vitro [46].
Phosphoglycerol dihydroceramides cause the most significant morphologic changes in
gingival fibroblasts suggesting either apoptosis and/or cell necrosis. This line of
evidence demonstrates the biological activity of these lipids and supports their inclusion
among several microbial virulence factors of P. gingivalis [46]. Interestingly, short chain
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ceramides have been shown to promote interleukin-1-mediated prostaglandin E 2
secretion from dermal fibroblasts [72], and COX-1 in fibroblasts [73]. However, specific
structure-function relationships of P. gingivalis dihydroceramides have yet to be
determined.
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OBJECTIVE

The aim of this investigation was to isolate P. gingivalis phosphoglycerol
dihydroceramides (PGDHC), unsubstituted PGDHC (PGDHC-C 15:0 ), free DHC (fDHC),
synthetic fDHC (A) and dephosphorylated PGDHC, and correlate structure with
biological activity based on human gingival fibroblast (HGF) prostaglandin secretory
response in vitro.
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MATERIALS AND METHODS

Lipid extraction from P. gingivalis

Previously, P. gingivalis (ATCC 33277, type strain) was inoculated into cooked meat
medium supplemented with trypticase, yeast extract, menadione, and hemin (BBL,
#295982, Becton Dickinson, Franklin Lakes, NJ). Once growth was established, the
initial culture was inoculated into enriched thioglycollate medium (BBL) and prereduced
blood agar plates. Batch suspension cultures were established after verification of
anaerobic growth of Gram-negative rods in thioglycollate medium and demonstration of
black-pigmented bacterial colonies on blood agar plates under anaerobic culture
conditions. Batch suspension cultures were grown in basal [peptone, trypticase, and yeast
extract, (BBL)] medium supplemented with hemin and menadione (Sigma; St. Louis,
MO) and brain heart infusion. The suspension cultures were incubated in an anaerobic
chamber flushed with N 2 (80%), CO 2 (10%), and H 2 (10%) at 37°C for five days, and the
bacteria were harvested by centrifugation (3,000 g for 20 min). Following lyophilization,
~4 g of P. gingivalis pellet was extracted overnight using a modification of the
phospholipid extraction procedures of Bligh and Dyer [47] and Garbus et al. [48].
Specifically, 4 ml of H 2 0 + 16 ml of MeOH-CHCl 3 (2:1; v/v) was added to the bacterial
sample and vortexed. After 12 h, 3 ml of 2 N KCl + 0.5 M K 2 HPO 4 and 3 ml CHCl 3
were added and the sample vortexed. The lower organic phase was carefully removed and
CHCl 3 (3 ml) was added to each sample and vortexed. The CHCl 3 phase was removed

13

and combined with the previous organic solvent extract. The lipid extract from P.
gingivalis was dried under nitrogen and stored frozen. This sample of frozen P.
gingivalis lipid extract was donated as a kind gift from Dr. Frank Nichols.

Lipid fractionation by HPLC

Direct phase HPLC (d-HPLC) [1 x 25 cm silica gel, 5 µm; Supelco, Inc., Bellefonte, PA]
was used for initial separation of bacterial lipids as well as repurification using hexaneisopropanol-water (6:8:0.75; v/v/v: solvent A) with isocratic elution [74]. Reverse phase
HPLC (r-HPLC) [250/4mm diatomaceous earth, 5 µm; Phenomenex] was used for
further purification of fDHC using propanol:acetontrile (2:3; v/v: solvent B) with
isocratic elution as well. In preparation for d-HPLC, lipid samples were dissolved in
solvent A to achieve a concentration of ~80 mg/ml. For each chromatographic separation,
~3 mg of lipid was applied and fractions were pooled for 25 column fractionations.
Samples were eluted at 2.0 ml/min with 1 min fractions collected. For r-HPLC, lipid
samples were dissolved in solvent B. For each chromatographic separation, ~1 mg of
lipid was applied and fractions 1-25 were collected. During fractionation, lipid samples
were continuously monitored at 205 nm with a UV-vis spectrophotometer. Fractions were
dried under nitrogen and stored at resuspended in 2 ml of solvent A.
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Electrospray mass spectral analysis

An additional 10 µl from each fraction was analyzed for dihydroceramide constituents
using electrospray-MS (ESI-MS). Electrospray mass spectrometry analysis was
accomplished using a Micromass Quattro II mass spectrometer system. Dihydroceramide
lipid fractions, dissolved in solvent A, were injected at a maximum concentration of 100
µg/ml. Lipid samples (10 µl) were infused at a flow rate of 20 µl/min. For electrospray
positive-ion analyses, the desolvation and inlet block temperatures were 100°C and
150°C, respectively, and the transcapillary potential was 3,500 volts. For electrospray
negative-ion analyses, the desolvation and inlet block temperatures were 80°C and
100°C, respectively, and the transcapillary potential was 3,000 volts. The cone voltage
was usually 30 volts, and the mass acquisition range was 0–2,000 amu for initial
electrospray MS analyses. Fractions containing specific dihydroceramide lipids were
pooled and repurified using the same column and elution conditions. The repurified lipids
were evaluated for dihydroceramide recovery using ESI-MS. A purified, synthetic fDHC
(A) was obtained from the University of Connecticut Storrs Department of Chemistry to
include in this investigation.

Preparation of test samples

Lipid recovery in each HPLC fraction was determined by drying 5 µl from each fraction
onto a microbalance tray and weighing the tray using a Cahn Electrobalance (Ventron
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Corporation, Cerritos, CA). Predetermined amounts of PGDHC, PGDHC-C 15:0 , A, and
fDHC were transferred in CHCl 3 to conical vials and dried. These selected HPLC
fractions were then dissolved in ethanol to achieve a final concentration of 0.25 µg/µl,
and 80 µl of each lipid fraction was deposited in 35 mm culture wells while the culture
dishes were maintained in a laminar flow hood. The ethanol was allowed to evaporate
overnight, leaving a lipid residue covering most of the culture well surface. Vehicle
control wells received only ethanol solvent. Lipids were deposited onto culture dishes in
this manner so that cells could be exposed to bacterial lipid fractions without introducing
organic solvent into the culture medium. In a second series of experiments, fDHC was
diluted to 0.0025 µg/µl, 0.025 µg/µl and 0.25 µg/µl, and 80 µl were deposited into each
respective 35 mm well for dose response comparison. PGDHC, PGDHC-C15:O, and A
were also examined in this second series of experiments.

Determination of biological activity with human gingival fibroblasts

Primary cultures of gingival fibroblasts were obtained using gingival tissue, harvested at
the time of periodontal surgery, from two separate patients and processed as previously
described [65]. Gingival tissue samples were obtained according to a protocol approved
by the University of Connecticut Health Center Institutional Review Board, and
participants provided written informed consent. Primary cultures of gingival fibroblasts
were grown in Minimal Essential Medium (MEM) supplemented with 10% fetal calf
serum, penicillin G (100 U/ml), streptomycin (100 µg/ml), and amphotericin B (0.25
µg/ml) (Sigma), and cells were passaged fewer than 10 times for these experiments. The
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cells were harvested using trypsin (0.1%, w/v) in Ca 2 +-, Mg 2 +-free phosphate-buffered
saline and resuspended in MEM to achieve a 1:3 dilution of cells for passaging. Cells
were cultured in an H 2 O-saturated, 5% CO 2 atmosphere at 37°C. Fibroblasts were
introduced to bacterial lipids by inoculation into culture wells to achieve a cell
number/surface area equivalent to confluent cultures. After 1 h of exposure to bacterial
lipids, 30 µl of culture medium containing human recombinant IL-1ß (final
concentration,10 ng/ml) (Immunex; Seattle, WA) was injected to each sample. After the
cultures were incubated for an additional 24 h, they were photographed at x100
magnification using an Olympus phase contrast light microscope. Photomicrographs of
the effects of P. gingivalis total lipid sample were included from a pilot experiment.
However, quantification of total lipid induced prostaglandin production was not included
in this experiment. Medium samples were then harvested and frozen.

Quantification of prostaglandin production by GC-MS

Prostaglandin E 2 (PGE 2 ), and prostaglandin F 2α (PGF 2α ) were quantified in medium
samples using a modification of the method of Luderer et al. [66], previously described
by Nichols [67]. Each medium sample was supplemented with 100 ng of D4- PGF 2α and
D4-PGE 2 . The fibroblast medium samples were thawed and the pH adjusted to pH 3.5
with concentrated formic acid. The acidified medium samples were then applied to
reverse-phase preparative columns [Supelclean, LC-18 SPE tubes, 6 ml; Supelco, Inc.]
mounted on a vacuum manifold. Before applying the medium samples, the C-18 columns
(3 ml) were regenerated by running sequentially 3 ml of 100% methanol followed by 3

17

ml of Ca 2 +-Mg 2 +-free phosphate-buffered saline (pH 3.5). Each acidified medium
sample was then applied to individual SPE columns, the columns were washed with 3 ml
of 25% methanol in water, and enriched prostaglandins were eluted with 3 ml of 100%
methanol. The resultant samples were then supplemented with 2 ml of 1% formic acid in
water, and the prostaglandins were extracted with 2 ml of chloroform. The chloroform
extracts were dried under nitrogen.
All derivatizing agents were obtained from Pierce Chemical Corp. (Rockford, IL).
Prostaglandin samples were derivatized using the method of Waddell, Blair, and Wellby
[68]. Prostaglandin samples were first treated with 2% methoxylamine hydrochloride in
pyridine (30 µl). After standing overnight at room temperature, the samples were dried
under nitrogen, dissolved in acetonitrile (30 µl), and treated with pentafluorobenzyl
bromide (35% v/v in acetonitrile, 10 µl) and diisopropylethylamine (10 µl). The samples
were vortexed, incubated for 20 min at 40°C, and evaporated under nitrogen. The residue
was then treated with bistrimethylsilyl-trifluoroacetamide (BSTFA, 50 µl) and allowed to
stand at room temperature for 4–5 days.
Derivatized products of hydroxy fatty acids, long-chain bases, and prostaglandins were
transferred to vials used for GC-MS automated sampling (crimp cap vials, 200 µl). GCMS was carried out on a Hewlett Packard (Avondale, PA) 5890-gas chromatograph
interfaced with a 5988A-mass spectrometer. Prostaglandin samples were applied to an
SPB-1 (12 m x 0.2 mm, 0.33 µm film thickness; Supelco, Inc.) column held at 100°C.
Prostanoid samples were analyzed using a temperature program of 5°C/min from 100°C
to 240°C. The injector block was held at 260°C, and the transfer tube was maintained at
280°C. Prostaglandin levels were quantified using selected ion monitoring of the
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characteristic base peak ions, and bacterial fatty acids and long-chain bases were detected
and interpreted through analysis of characteristic spectra.

NMR analysis of fDHC

NMR data were collected on a Bruker (Rheinstetten, Germany) DRX-400, a Bruker
Avance 500, and a Varian (Palo Alto, CA) INOVA 600 (operating frequencies 400.144
MHz, 500.13 MHz, and 599.75 MHz, respectively). For bacterial fDHC, HPLC fractions
14 and 15 lipids dissolved in a mixture of deuterated solvents (CDC l3 -CD 3 OD). These
data allowed the assignment of proton resonances of the dihydroceramide base and the
phosphate side-chain of the molecule, as well as specific components of the aliphatic
chains. A mixture of solvents was necessary in order to prevent aggregation into micelles
or reverse micelles, depending on the solvent. Synthetic fDHC (A) was aliquoted,
dissolved in a mixture of deuterated solvents (CDC l3 -CD 3 OD) and analyzed in a similar
fashion. This further allowed for comparison between synthetic (A) and P. gingivalis
fDHC.

Statistical Analysis

Test groups were compared to ethanol vehicle and each other using analysis of
variance (ANOVA) after calculation of test/control (T/C) ratios. Fisher PLSD, Scheffe
F-test and Dunnett t were used to determine significance of ANOVA at 95% confidence
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level. Statistical analysis was computed using a computer software package for
Macintosh (StatView).
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RESULTS

P. gingivalis bacterial complex lipid structures with corresponding mass to charge
ratio (m/z) including PGDHC, PGDHC-C 15:0 , and fDHC can be seen in (Fig. 1). Lipids
were extracted from P. gingivalis and separated by dHPLC and rHPLC. Several
dihydroceramide lipid moieties can be observed in the ESI-MS spectrum for the P.
gingivalis total lipid sample in (Fig. 2). Samples of PGDHC were obtained by dHPLC
separation of the total lipid extract, and purity of samples was confirmed with ESI-MS
analysis (Fig. 3). PGDHC-C 15:0 was obtained by NaOCH 3 treatment of an aliquoted
sample of PGDHC, separated by dHPLC, and purity of the samples was confirmed with
ESI-MS analysis (Fig. 4). High purity of samples can be noted by comparison of relative
ion abundance of m/z peaks corresponding to each separated dihydroceramide.
Corresponding solvent ESI-/+M spectrum is located below the separated
dihydroceramide spectrum in each figure.
Pure samples of fDHC were obtained using rHPLC. A sample of a UV-vis
spectrum for fDHC fractionation after initial rHPLC separation is shown in Fig. 5 where
fDHC elution from column is delayed and can be observed in the later peak. After
collection and pooling of these corresponding fractions, rHPLC was used a second time
(Fig. 6). In this UV-vis spectrum, the largest signal corresponds with refined separation
of fDHC. These fractions containing fDHC were analyzed with ESI+MS and this mass
spectrum can be seen in Fig. 7. As previously described, synthetic fDHC was provided
by the University of Connecticut Storrs Department of Chemistry. After synthesis and
purification, characterization was performed similarly with addition of NMR
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spectroscopic analysis. ESI+MS for synthetic dihydroceramide (A) can be seen in Fig. 8.
NMR spectra for both fDHC and A can be observed together for comparison in Fig. 9.
An impressive similarity is noted including the finger print region between both spectra.
The ESI+MS and the NMR data provide strong evidence of structural similarity between
fDHC and A.
Morphologic changes of human gingival fibroblasts (HGF) were evaluated after
24 hours of exposure to lipid or ethanol vehicle in addition to 30 ng IL-1ß in 35mm wells
with phase contrast microscopy. Photomicrographs for HGF exposure can be observed in
Fig. 10. Morphologic changes could not be observed for ethanol vehicle (Panel A)
and/or fDHC (Panel D). However, morphologic changes appearing as severe atrophy
and apoptosis were observed after 24 hours of exposure to 20µg of PGDHC + 30 ng IL1ß (Panel C) and 20µg Total Lipid extract + 30 ng IL-1ß (Panel B) in 35mm wells.
Treatment of HGF with P. gingivalis PGDHC, PGDHC-C 15:0 , and fDHC as well
as synthetic free DHC demonstrated varying potentiation of IL-1ß mediated PGE 2
secretion for both 20µg dose and fDHC dose response of 0.2, 2.0, and 20µg when
compared to vehicle control. PGF 2α secretion was unaffected by bacterial and synthetic
lipids (Fig. 11). In a separate experiment comparing the effects of PGDHC-C 15:0 , a trend
suggesting stimulation of HGF PGE 2 secretion was noted for all lipids, but statistical
significance was not achieved (Fig. 12). Although trends were noted for stimulation for
all treatment groups compared to control, statistical significance was only noted for
PGDHC (20µg ) and fDHC (20µg ) (Fig 13). A trend for increased PGE 2 secretion with
increasing concentration of fDHC was also noted, but did not achieve statistical
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significance (Fig. 14). The effects of all samples on HGF PGE 2 and PGF 2α secretion
was determined by calculating treatment/control (T/C) for Figures 12-14.
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DISCUSSION

This present investigation demonstrates that, in vitro, P. gingivalis PGDHC,
PGDHC-C 15:0 , fDHC, and synthetic fDHC differentially induce IL-1β mediated HGF
secretion of PGE 2 . HGF secretion of PGF 2α was unaffected by P. gingivalis and
synthetic dihydroceramides. PGDHC and fDHC treated HGF resulted in similar PGE 2
synthesis approximately 1.8 fold compared to ethanol vehicle (p < .05).
Several proinflammatory cytokines including IL-1β [75], tumor necrosis factor α
[76], epidermal growth factor [77], and transforming growth factor β [78] are known to
stimulate PGE 2 production. Prostaglandin synthesis is regulated by the activity of both
phospholipase A 2 and cyclooxygenase (COX) [79]. Previous investigation has elucidated
that the rate-limiting step to prostaglandin synthesis is related to COX stability since it is
rapidly degraded and has a short half-life [80]. Adding to the complexity of this
mechanism, IL-1 induced COX synthesis is mediated by protein-dependent posttranscriptional events [81, 82]. Progressively, in vitro, examination of human dermal
fibroblast IL-1-mediated PGE 2 secretion has determined that spingosine and C2ceramide treatment resulted in an 8-fold induction of COX mRNA within 1-2 hours.
Although lacking a phosphate head group and isobranched fatty acid linkage, C2
ceramide has a structure relatively similar to P. gingivalis dihydroceramides. Given these
findings, as found for human dermal fibroblasts, a similar mechanism is expected where
P. gingivalis and synthetic lipid samples tested in this study may increase COX
expression accounting for the observed enhancement of IL-1β mediated PGE 2
production.
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More specifically, increased sulcular concentration of IL-1β and PGE 2 has been
previously shown to regulate the magnitude of tissue destruction in progressive
periodontitis [83-88]. IL-1 is a proinflammatory cytokine that has a large array of
biological activities and directly regulates several genes expressed during inflammation
[89]. There are two principal forms of IL-1 with agonist activity: IL-1α and IL-1β. A
third ligand, IL-1ra, is an antagonist that functions as a competitive inhibitor. Two IL-1
receptors are found on the surface of target cells: IL-1 receptor-1 and IL-1 receptor-2.
IL-1 is produced by many cell types including monocytes/macrophages, neutrophils,
fibroblasts (gingival and periodontal ligament), epithelial cells, endothelial cells, and
osteoblasts [90-93], and can induce upregulation of adhesion molecules on leukocytes
and endothelial cells, stimulate production of chemokines, increase production of
prostaglandins, matrix metalloproteinases, and even enhance bacterial killing and
phagocytic activity [89, 94]. There are several lines of evidence that implicate IL-1 in the
pathogenesis of periodontal disease [95-97]. Furthermore, experimental evidence
suggests that susceptibility to periodontal disease is influenced by genetic polymorphisms
of the IL-1 gene [98, 99]. Interestingly, IL-1 gene polymorphisms have also been
associated with poorer periodontal prognosis in smokers where risk of tooth loss
increased up to 7.7 times over a 14-year periodontal maintenance period [100].
Impressive levels of IL-1 have been recovered in gingival crevicular fluid (GCF) in
patients with periodontal disease compared to healthy controls. According to Salvi et al.,
GCF IL-1 levels were approximately 17 ng/ml for healthy controls, 116 ng/ml for
gingivitis patients, 263 ng/ml for chronic periodontitis patients and as high as 458 ng/ml
for aggressive periodontitis patients [101]. Similarly, many studies have reported that
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GCF PGE 2 levels are significantly elevated in patients with periodontal disease compared
to healthy controls. In a monkey model, previous investigation has shown that crevicular
fluid concentration of PGE 2 may be elevated up to threefold during only two months of
periodontitis progression [83]. In the same model, with a placebo-controlled doubleblinded study, this group has also demonstrated that local administration of a nonsteroidal anti-inflammatory agent (Ketoprofen cream) significantly reduced crevicular
fluid PGE 2 concentration with corresponding gain in alveolar bone over a 6 months
follow up period. Confirmed in a human model of experimental gingivitis, increased
GCF PGE 2 levels were found at 4 weeks following cessation of oral hygiene procedures
[85]. According to Seymour et. al., GCF PGE 2 levels (ng/ml) were as high 20, 50, 42,
82, and 90 examining 21 healthy, 28 gingivitis, 21 periodontitis, 15 aggressive
periodontitis, and 15 refractory periodontitis patients, respectively [84]. In review of
these findings, it seems clear that IL-1 and PGE 2 are highly important inflammatory
mediators implicated in the pathogenesis of periodontitis.
Previous literature has demonstrated that 3-OH isoC 17:0 is readily recovered in
both organic and aqueous solvent extracts of plaque samples, teeth and root sections
substantiating the presence of bacterial complex lipid and LPS levels, respectively. This
bacterial hydroxy fatty acid is only recovered from lipid extracts of P. gingivalis,
Prevotella, Bacteroides, Capnocytophaga [102, 103], Flavobacterium [104, 105], and
Myxobacteria [106], but not synthesized by mammalian tissues.
These findings are similar to results found previously examining the effects of P.
gingivalis total lipid extract and PGDHC on HGF cultures, in vitro [46]. However, in this
study, less impressive recovery of PGE 2 was noted. This finding may be a result of
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response variation between subjects or associated with prolonged age of the cell cultures.
Genetic variation of fibroblast phenotype, although not related to secretion of
prostanoids, has been exhaustively demonstrated in association with hereditary gingival
fibromatosis [107]. Given this information, one could conclude that it is quite possible to
have a broad range of HGF responsiveness when exposed to P. gingivalis lipids.
Although HGF were passaged less than ten times, this treatment occurred over a period
of approximately eight months. A more representative HGF synthesis of PGE 2 would be
expected with increased sample size of subjects for biopsy and decreased storage time of
HGF clones. In consideration of these limitations, future investigations will include
increased numbers of subjects willing to donate biopsy samples as well as completion of
testing within a shorter time frame.
LPS is a devastating virulence factor of P. gingivalis, Aggregatibacter
actinomycetemcomitans, as well as other Gram-negative bacteria. LPS acts as a microbeassociated molecular pattern recognized through pattern-recognition receptors on resident
immune and non-immune cells within the periodontium [108]. As a result, inflammatory
cells are recruited, osteoclasts are activated, and prostanoids, lytic enzymes, and
proinflammatory cytokines are secreted [109, 110]. Murine models have been used to
demonstrate the devastating effects localized LPS injection has on the periodontium
including severe inflammation and alveolar bone loss. Historically, these studies isolated
LPS from non-periopathogenic bacteria including Escherichia coli or Salmonella
typhimurium [111-113]. However, more recently, Rogers et al. observed that local
injection of A. actinomycetemcomitans LPS in Sprague-Dawley rats induced severe bone
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loss over an 8 week period using micro-computed tomography and histologic evaluation
[114].
The available literature clarifies the virulence potential of both bacterial complex
lipids and LPS to play a direct role in periodontal pathogenesis. Although both of these
lipid groups are components of the bilayer membrane of certain bacteria involved in
periodontal disease, controversial evidence suggests that the recovery of LPS in diseased
gingival tissues may be less than expected. As stated previously, long-chain 3-hydroxy
fatty acids are covalently linked to the lipid A component of LPS as well as the long
chain base of bacterial complex lipids of P. gingivalis, Prevotella, Bacteroides,
Capnocytophaga [102, 103], Flavobacterium [104, 105], and Myxobacteria [106], but
not synthesized by mammalian tissues. After extraction procedures, Nichols (1994)
found that LPS 3-hydroxy iC 17:0 and bacterial complex lipid 3-hydroxy iC 17:0 are
recovered in the aqueous and organic phase, respectively [45]. Subsequently, both LPS
and bacterial complex lipid distribution were determined for two periodontal pathogens
(P. gingivalis and Prevotella intermedia), subgingival plaque samples and gingival tissue
samples both isolated from gingivitis and severe periodontitis sites. Mean values of 3hydroxy iC 17:0 recovered in organic solvent extracts of P. gingivalis and P. intermedia
strains ranged from 56-63% and only < 5% of the total 3-hydroxy iC 17:0 , respectively.
Organic solvent extract of subgingival plaque samples contained 75% of the total 3hydroxy iC 17:0 for periodontitis subjects and only 43% for gingivitis subjects. Finally, for
gingival tissue samples, 3-hydroxy iC 17:0 was primarily recovered only in organic solvent
extracts of both healthy and mildly inflamed and periodontitis gingival tissue samples. In
conclusion, these results indicate that LPS from these organisms is not present in

28

substantial levels in diseased gingival tissues. Furthermore, the significant recovery of 3hydroxy iC 17:0 in organic solvent from periodontitis plaque samples and gingival tissue
suggests that bacterial complex lipid, from the aforementioned select bacterial species,
may be responsible for a more significant fraction of the lipid component of periodontal
pathogenesis.
Of clinical relevance, adequate removal of lipids for experimental purposes
requires the use of toxic organic solvents such as chloroform [42]. Since these structures
are extremely hydrophobic, their removal during routine non-surgical and surgical
therapy will be limited to mechanical debridement of cementum and locally inflamed soft
tissue. Significant amounts of lipid remaining on the root surface are expected since they
are insoluble by aqueous irrigation, and mechanical debridement of teeth to remove
calculus is limited even with adequate surgical access [115]. Removal of bacterial
complex lipids in inflamed gingival tissues with resective periodontal surgery may be
related to the observation of decreased units of gingival inflammation, evident in 6 month
follow-up biopsy samples, compared to non-resective [116]. Furthermore, the
persistence of lipid on the root surface may also have limiting effects on regeneration
potential of the periodontium. Not only were the HGF significantly reactive to the
presence of both PGDHC and P. gingivalis fDHC, as evident by secretion of PGE 2 , but
the majority of photomicrographs taken of HGF exposed to PGDHC revealed cellular
morphological changes suggestive of apoptosis.
Of the bacterial lipids and synthetic fDHC examined, HGF morphologic changes
were only noted for PGDHC; additionally, the majority of PGDHC experiments resulted
in appearance of cellular changes observed with phase contrast microscopy. A potential
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explanation for this finding may be the presence of both a phosphate head group and an
ester-linked 3-OH 15-carbon isobranched fatty acid. This unique combination of these
structural elements of PGDHC may be specific for the molecule’s biologic activity on
HGF in vitro. Interestingly, LPS lipid A contains two phosphate groups coupled to
glucosamines, and previous investigation has shown that removal of one of these
phosphate groups generates a monophosphoryl lipid A that is 100-fold less toxic than the
unmodified lipid A [117]. Alkaline phosphatases have been shown to modify LPS by
dephosphorylating its lipid A moiety [118-121]. Alkaline phosphatase is a glycoprotein
and membrane bound enzyme that increases local concentrations of phosphate ions [122].
In the periodontium, alkaline phosphatase is a very important enzyme as it is part of the
normal turnover of the periodontal ligament, root cementum formation and maintenance,
and bone homeostasis [122]. It is produced by fibroblasts, osteoblasts, osteoclasts, as
well as many other cells, but the primary source of alkaline phosphatase in gingival
crevicular fluid is neutrophils [122] where it functions in superoxide generation, an
important defense mechanism of this cell [123]. In a more recent investigation, using a
zebrafish model, Guillemin and coworkers have demonstrated the LPS detoxifying
effects of alkaline phosphatase [124]. No effect on survival was noted when wild-type
animals were exposed to LPS and when animals with blocked expression of intestinal
alkaline phosphatase were exposed to previously dephosphorylated LPS via calf intestinal
alkaline phosphatase. However, when animals with blocked expression of intestinal
alkaline phosphatase were exposed to LPS, toxic effects were readily apparent with 100%
mortality within the following 48-hour time period after administration. These authors
conclude that intestinal alkaline phosphatase protects these animals from the toxic effects
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of LPS, and that “commensal” flora may actually be toxic in the absence of this adaptive
physiology. In this experiment, bacterial fDHC and PGDHC stimulated IL-1β HGF
PGE 2 secretion was similar despite the absence of the phosphate head group in the fDHC
organic structure. Aside from the minimal recovery of LPS from plaque and gingival
tissue samples from patients with periodontitis as mentioned previously, possible
protection of LPS toxicity by GCF alkaline phosphatase dephosphorylation warrants
further investigation. Future experimentation examining the effects of bacterial complex
lipid and LPS phosphate groups may lead to a better understanding of structure function
relationships and the role of alkaline phosphatase in periodontal disease mechanisms.
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CONCLUSION

Further studies are needed to evaluate the structure function relationship of
bacterial complex lipids and LPS as well as the potential protective effect of alkaline
phosphatase in periodontal diseases. Larger sample sizes may clarify the potential effects
of these various structural elements as well as dose response relationships. Other future
investigations including effects on osseointegration, development of multiple sclerosis in
a murine model, and the removal of lipids from contaminated root surfaces are either
planned or currently in progress.
In summary, through the use of reverse and direct phase HPLC, pure samples of
P. gingivalis PGDHC, PGDHC-C 15:0 , and fDHC were obtained and confirmed with ESIMS (ESI+MS for fDHC). Synthetic fDHC was obtained from the University of
Connecticut Storrs graduate chemistry department, and molecular structure was
confirmed using ESI+MS and NMR with consistent comparison to P. gingivalis fDHC.
In vitro, P. gingivalis PGDHC, PGDHC-C 15:0 , fDHC, and synthetic fDHC differentially
induce IL1-β mediated HGF secretion of PGE 2 . HGF secretion of PGF 2α was unaffected
by P. gingivalis and synthetic dihydroceramides. PGDHC and fDHC treated HGF
resulted in similarly increased PGE 2 synthesis approximately 1.8 fold compared to
ethanol vehicle (p < .05). In addition, morphologic changes suggestive of HGF atrophy
and apoptosis were evident only for PGDHC, and this was noted for the majority of
PGDHC experiments.
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Figure 1. Chemical structures of P. gingivalis complex lipids are given with
corresponding mass to charge ratios (m/z). PGDHC consists of a fatty acid, 3-OH
isoC 17:O , and a long chain base that varies from 17-19 carbons in length. When PGDHC
is treated with NaOCH 3 , resultant de-esterification yields unsubstituted PGDHC (unsub
PGDHC) which is essentially structurally identical to PGDHC minus a 15-carbon
isobranched methyl ester. Both PGDHC and Unsub PGDHC contain a phosphoglycerol
head group. Free DHC is structurally identical to unsub PGDHC minus the
phosphoglycerol head group. Two other previously investigated P. gingivalis lipids,
phosphoethanolamine and phosphatidylethanolomine, were not tested in this experiment,
but were included in this figure for completeness. Figure was provided by Frank Nichols.
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Figure 2. ESI – spectrum of total lipid extract of P. gingivalis. Predominant ion
abundances (m/z: 960, 946, 932) correspond to PGDHC. Lower spectrum corresponds to
solvent.
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Figure 3. ESI - spectrum of PGDHC fractions after separation of P. gingivalis total lipid
extract with dHPLC. Purity of sample can be appreciated by comparing relative ion
abundances between PGDHC (m/z: 960, 946, 932) seen in upper spectrum and solvent in
lower spectrum.
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Figure 4. ESI - spectrum of PGDHC – C 15:0 fractions after separation of P. gingivalis
total lipid extract with dHPLC. Again, purity of sample can be determined by
comparison of relative ion abundance between PGDHC-C 15:0 and other signals including
solvent spectrum below. High ion abundance signal to the left in the spectrum
corresponds to negligible fatty acid moieties.
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Figure 5. UV-vis spectrum of rHPLC at 205 nm. Second peak corresponds to fDHC
determined by ESI + mass spectrometry (not shown).
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Figure 6. UV-vis spectrum monitored at 205 nm of fDHC fraction collected from first
separation of P. gingivalis. Free DHC fraction corresponds with strongest peak
determined by ESI + mass spectrometry (shown in Figure 7).

38

Figure 7. ESI + spectrum of P. gingivalis fDHC fractions after separation P. gingivalis
total lipid extract with rHPLC. Purity of sample can be appreciated by comparing relative
ion abundances between fDHC (m/z: 584, 570, 556) seen in upper spectrum and solvent
in lower spectrum.
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Figure 8. ESI + spectrum of synthetic fDHC fraction (A). Purity of sample can be
appreciated by comparing relative ion abundances between synthetic fDHC (A) with an
isobranched C 17:0 long chain base (m/z: 556) seen in upper spectrum and solvent in lower
spectrum.
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Figure 9. NMR spectra of P. gingivalis fDHC fractions (red and blue spectra) and
synthetic fDHC (black spectrum). A high degree of similarity between bacterial and
synthetic fDHC can be appreciated.
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Panel A

Panel B

Panel C

Panel D

Figure 10. Phase contrast photomicrographs at 100x magnification of HGF in 35mm
culture wells with ethanol vehicle (Panel A), total lipid extract (Panel B), PGDHC (Panel
C), and fDHC (Panel D) for 24 hours. Normal HGF morphology is noted for ethanol
vehicle and fDHC (Panels A and D). Cellular apoptosis is noted for Total lipid extract
and PGDHC (Panels B and C).
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Figure 11. Comparison of HGF production of PGE 2 and PGF 2α . Error bars represent
standard deviations for each sample.

43

2

n=3

Synthetic FDHC (20 ug)

n=3

0

P. g. FDHC ( 20 ug)

1

PG DHC (20 ug)

PGE 2 (T/C)

n=3

Unsub PG DHC (20 ug)

n=3

Fibroblast Treatment

Figure 12. Prostaglandin release given as treatment/control (T/C) for each sample
examined. Ethanol control is not shown. Error bars represent standard deviations.
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Figure 13. Prostaglandin release given as treatment/control (T/C) for each sample
examined. Ethanol control is not shown. Error bars represent standard deviations.
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Figure 14. Prostaglandin release given as treatment/control (T/C) for each sample
examined. Ethanol control is not shown. Error bars represent standard deviations.
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